299 related articles for article (PubMed ID: 32480422)
1. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Ranger A; Haji R; Kaczmarski R; Danga A
Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
[No Abstract] [Full Text] [Related]
2. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
3. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
Gautier-Vargas G; Baldacini C; Benotmane I; Keller N; Perrin P; Moulin B; Caillard S
Kidney Int; 2020 Aug; 98(2):508-509. PubMed ID: 32505467
[No Abstract] [Full Text] [Related]
4. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
5. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
Henderson LA; Canna SW; Schulert GS; Volpi S; Lee PY; Kernan KF; Caricchio R; Mahmud S; Hazen MM; Halyabar O; Hoyt KJ; Han J; Grom AA; Gattorno M; Ravelli A; De Benedetti F; Behrens EM; Cron RQ; Nigrovic PA
Arthritis Rheumatol; 2020 Jul; 72(7):1059-1063. PubMed ID: 32293098
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.
Carnero Contentti E; Correa J
Mult Scler Relat Disord; 2020 Jun; 41():102097. PubMed ID: 32278860
[No Abstract] [Full Text] [Related]
7. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
[TBL] [Abstract][Full Text] [Related]
8. A plea for the pathogenic role of immune complexes in severe Covid-19.
Vuitton DA; Vuitton L; Seillès E; Galanaud P
Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
[No Abstract] [Full Text] [Related]
9. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.
Zhang X; Song K; Tong F; Fei M; Guo H; Lu Z; Wang J; Zheng C
Blood Adv; 2020 Apr; 4(7):1307-1310. PubMed ID: 32243501
[TBL] [Abstract][Full Text] [Related]
10. Is a "Cytokine Storm" Relevant to COVID-19?
Sinha P; Matthay MA; Calfee CS
JAMA Intern Med; 2020 Sep; 180(9):1152-1154. PubMed ID: 32602883
[No Abstract] [Full Text] [Related]
11. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
Jiménez-Brítez G; Ruiz P; Soler X
Med Clin (Barc); 2020 Nov; 155(9):410-411. PubMed ID: 32718713
[No Abstract] [Full Text] [Related]
12. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
13. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Cai S; Sun W; Li M; Dong L
Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
[TBL] [Abstract][Full Text] [Related]
14. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
Smetana K; Brábek J
In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
[TBL] [Abstract][Full Text] [Related]
15. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
16. May IL-17 have a role in COVID-19 infection?
Megna M; Napolitano M; Fabbrocini G
Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777
[No Abstract] [Full Text] [Related]
17. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Mojtabavi H; Saghazadeh A; Rezaei N
Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab administration in a refractory case of COVID-19.
Dastan F; Nadji SA; Saffaei A; Tabarsi P
Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524
[No Abstract] [Full Text] [Related]
19. IL-6: Relevance for immunopathology of SARS-CoV-2.
Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
[TBL] [Abstract][Full Text] [Related]
20. Immune status could determine efficacy of COVID-19 therapies.
Cully M
Nat Rev Drug Discov; 2020 Jul; 19(7):431-434. PubMed ID: 32546768
[No Abstract] [Full Text] [Related]
[Next] [New Search]
